SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven low-cap memecoin on Solana, with investors actively discussing its rapid growth and the developer's commitment to community engagement through frequent airdrops and transparency. Supporters are rallying behind the project's 'dumb send' philosophy, frequently comparing its early-stage potential to other successful runners while focusing on social media trending and viral expansion.

Optical Cable Corp. engages in the business of manufacturing fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment, specialty markets, and the wireless carrier market offering integrated suites of high-quality products which operate as a system solution or seamlessly integrate with other components. Its products include fiber optic and copper cabling, hybrid cabling, fiber optic and copper connectors, specialty fiber optic, copper and hybrid connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multimedia boxes, fiber optic reels, and other cable and connectivity management accessories. The company was founded on June 10, 1983 and is headquartered in Roanoke, VA.

Optical Cable Corp.

Optical Cable Corp is trending as investors monitor its role in the data center and fiber infrastructure boom, with the community closely tracking potential execution of its strategic partnership with Lightera. While sentiment remains divided between those betting on long-term value from increased fiber demand and those wary of the stock's low-float volatility and historical revenue headwinds, the ticker continues to attract attention during retail momentum cycles.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts International is drawing attention following the submission of a significant 2.3 billion dollar proposal for a new casino license in New York, a move seen by the community as a key strategy to expand its East Coast footprint. While investors weigh this regulatory catalyst against broader economic concerns, discussions remain split between the stock's long-term potential in the gaming sector and the immediate impact of market-wide volatility on consumer discretionary spending.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened community engagement driven by anticipation surrounding ongoing monthly burn initiatives and the development of new ecosystem projects. Supporters are closely watching the chart for signs of a turnaround, frequently discussing the potential for a long-term recovery and increased utility within the blockchain.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh its attractive dividend yield, aggressive share buyback programs, and low valuation against sector-wide headwinds and concerns about debt levels. The community is actively debating whether these factors signal a deep-value opportunity or a long-term value trap in the frozen food space.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is trending as investors weigh its role as a "picks-and-shovels" play in the automotive and industrial AI buildout against recent analyst downgrades citing inventory and demand concerns. The community is actively debating whether its recent price action signals a long-term value opportunity or a trap amid broader volatility in the semiconductor sector.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

The $AIRCOIN community is rallying behind the project's long-term vision, emphasizing its unique 'Airlock' mechanism which has over 38% of the supply locked on-chain to demonstrate deep investor conviction. Supporters frequently highlight the project's historical lore, battle-tested leadership, and growing treasury as key differentiators that position it as a durable, fundamentally-driven alternative to short-lived meme trends.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

Planet Fitness, Inc. engages in the operation and franchising of fitness centers. It operates through the following segments: Franchise, Corporate-Owned Clubs, and Equipment. The Franchise segment includes operations related to the company's franchising business in the United States, Puerto Rico, Canada, Panama, Mexico, and Australia. The Corporate-Owned Clubs segment consists of operations with respect to all corporate-owned clubs throughout the United States, Canada, and Spain. The Equipment segment involves the sale of equipment to franchisee-owned clubs in the United States, Canada, and Mexico. The company was founded by Michael Grondahl and Marc Grondahl in 1992 and is headquartered in Hampton, NH.

Planet Fitness Inc - Ordinary Shares - Class A

Planet Fitness is under intense pressure as the company faces a growing community-led boycott and increased scrutiny following controversies over its locker room policies. Investors are debating the stock's valuation as the market watches to see if this reputational backlash and rising membership cancellations will meaningfully impact the company's long-term growth and financial outlook.

Churchill Downs, Inc. is a provider of pari-mutuel horse racing, online account wagering on horse racing and casino gaming. It operates through the following segments: Live and Historical Racing, Wagering Services and Solutions, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing related revenue and expenses at Churchill Downs Racetrack and historical racing properties in Kentucky, Virginia, and New Hampshire. The Wagering Services and Solutions focuses on the revenue and expenses from pari-mutuel wagers through TwinSpires, retail and online sports betting business, United Tote Company, and Exacta Systems, LLC. The Gaming segment is involved in the casino properties and associated racetracks which support the casino license. The company was founded in 1875 and is headquartered in Louisville, KY.

Churchill Downs, Inc.

Churchill Downs is trending as investors weigh recent quarterly performance and strategic expansions against competitive pressures in the gaming and sports wagering sector. The community is actively discussing the company's growth trajectory and ongoing capital projects, alongside its relative valuation compared to other industry players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

<ul class="summary-bullets"><li>Merck said it will reorganize its human health segment into two separate units.</li><li>Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International.&nbsp;</li><li>The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard.</li></ul>Merck &amp; Co. Inc. (MRK) announced on Monday that it is overhauling the leadership structure of its flagship pharmaceutical division as the company prepares for looming revenue headwinds tied to its top-selling cancer therapy.&nbsp;The Rahway, New Jersey-based drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.<h2 class="st-heading-2">Preparing For Keytruda Patent Expiration</h2>One of the units will concentrate on&nbsp;Oncology business, while the other will house the specialty, pharma, and infectious diseases business.&nbsp;According to the Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65">report</a>, the restructuring comes as Merck braces for the loss of U.S. market exclusivity for Keytruda in 2028, a development expected to invite lower-priced competition and dent sales.&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merck stock</a> traded over 1% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory, with message volume shifted to ‘low’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">New Leadership To Drive Growth&nbsp;</h2>To guide the oncology-focused arm, Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International. The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard, who will join Merck effective March 2.&nbsp;<h2 class="st-heading-2">Building Beyond Keytruda&nbsp;</h2>According to the report, Merck has spent heavily on acquisitions in recent years to bolster its pipeline and cushion the anticipated slowdown in Keytruda sales.“As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma &amp; Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating long‑term value for our stakeholders.”-Robert M. Davis, Chairman and CEO, Merck&nbsp;Merck said it currently has roughly 80 Phase 3 trials underway and anticipates launching more than 20 new growth drivers in the coming years, most of which it believes could achieve blockbuster status.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-tomz-stock-soaring-pre-market-today-a-key-uk-approval-may-be-the-catalyst/cZRt8hkR4y4">Why Is TOMZ Stock Soaring Pre-Market Today? A Key UK Approval May Be The Catalyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Splits Oncology, Specialty Operations To Brace For Keytruda Patent Loss – Overhauls Leadership To Drive Growth 

The drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

Current Price	$103.98
Prev Close	$104.77
Open	$104.54
Dividend Yield	N/A
50-Day Moving Average	$105.04
Beta	N/A
Avg. Volume	12,004.65
PE Ratio	N/A

52-Week High	$110.81
52-Week Low	$77.69
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF